Goldman Sachs Group Inc Prothena Corp Public LTD CO Transaction History

Goldman Sachs Group Inc

  • $605 Billion
  • Q3 2024

A detailed history of Goldman Sachs Group Inc transactions in Prothena Corp Public LTD CO stock. As of the latest transaction made, Goldman Sachs Group Inc holds 415,289 shares of PRTA stock, worth $5.91 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
415,289
Previous 350,130 18.61%
Holding current value
$5.91 Million
Previous $7.23 Million 3.86%
% of portfolio
0.0%
Previous 0.0%

Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024
BUY
$16.73 - $24.79 $1.09 Million - $1.62 Million
65,159 Added 18.61%
415,289 $6.95 Million
Q2 2024

Aug 13, 2024
BUY
$19.54 - $26.15 $805,888 - $1.08 Million
41,243 Added 13.35%
350,130 $7.23 Million
Q1 2024

May 15, 2024
SELL
$24.75 - $40.66 $616,250 - $1.01 Million
-24,899 Reduced 7.46%
308,887 $7.65 Million
Q4 2023

Feb 13, 2024
BUY
$32.31 - $52.32 $2.7 Million - $4.37 Million
83,463 Added 33.34%
333,786 $12.1 Million
Q3 2023

May 14, 2024
SELL
$47.3 - $70.6 $3.95 Million - $5.89 Million
-83,463 Reduced 25.0%
250,323 $12.1 Million
Q3 2023

Nov 14, 2023
BUY
$47.3 - $70.6 $2.73 Million - $4.07 Million
57,688 Added 29.95%
250,323 $12.1 Million
Q2 2023

May 14, 2024
SELL
$48.26 - $78.59 $1.57 Million - $2.55 Million
-32,442 Reduced 14.41%
192,635 $13.2 Million
Q2 2023

Aug 14, 2023
SELL
$48.26 - $78.59 $1.57 Million - $2.55 Million
-32,442 Reduced 14.41%
192,635 $13.2 Million
Q1 2023

May 14, 2024
BUY
$46.97 - $58.27 $423,763 - $525,711
9,022 Added 4.18%
225,077 $10.9 Million
Q1 2023

May 11, 2023
BUY
$46.97 - $58.27 $423,763 - $525,711
9,022 Added 4.18%
225,077 $10.9 Million
Q4 2022

May 14, 2024
SELL
$52.05 - $65.0 $2.63 Million - $3.28 Million
-50,482 Reduced 18.94%
216,055 $13 Million
Q4 2022

Feb 13, 2023
SELL
$52.05 - $65.0 $2.63 Million - $3.28 Million
-50,482 Reduced 18.94%
216,055 $13 Million
Q3 2022

May 14, 2024
SELL
$25.16 - $60.63 $91,758 - $221,117
-3,647 Reduced 1.35%
266,537 $16.2 Million
Q3 2022

Nov 10, 2022
SELL
$25.16 - $60.63 $91,758 - $221,117
-3,647 Reduced 1.35%
266,537 $16.2 Million
Q2 2022

May 14, 2024
SELL
$22.73 - $39.98 $1.45 Million - $2.54 Million
-63,602 Reduced 19.05%
270,184 $7.34 Million
Q2 2022

Aug 15, 2022
BUY
$22.73 - $39.98 $264,145 - $464,607
11,621 Added 4.49%
270,184 $7.34 Million
Q1 2022

May 16, 2022
BUY
$30.27 - $49.22 $1.35 Million - $2.19 Million
44,447 Added 20.76%
258,563 $9.46 Million
Q4 2021

Feb 14, 2022
BUY
$42.11 - $73.26 $5.82 Million - $10.1 Million
138,207 Added 182.07%
214,116 $10.6 Million
Q3 2021

Nov 10, 2021
BUY
$48.2 - $78.89 $3.66 Million - $5.99 Million
75,909 New
75,909 $5.41 Million

Others Institutions Holding PRTA

# of Institutions
185
Shares Held
42.8M
Call Options Held
162K
Put Options Held
102K
View Full List

About PROTHENA CORP PUBLIC LTD CO

PRTA Quotes by TradingView
  • Ticker PRTA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,922,800
  • Market Cap $668M
  • Description
  • Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a human...
More about PRTA
Track This Portfolio

Track Goldman Sachs Group Inc Portfolio

Follow Goldman Sachs Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email